Gastric cancer (GC) is one of the most common malignancies worldwide. Most patients are
diagnosed at advanced stages due to the subtle symptoms of earlier disease and the low …

Tumours employ various tactics to adapt and eventually resist immune attack. These
mechanisms are collectively called adaptive immune resistance (AIR). The first defined and …

More than 1 million (1 089 103) new cases of gastric cancer were estimated globally in
2020, resulting in 768 793 deaths. 1 These burden estimates will continue to increase due to …

Background Pembrolizumab has shown improved progression-free survival versus
chemotherapy in patients with newly diagnosed microsatellite instability-high or mismatch …

Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) amplification or
overexpression occurs in approximately 20% of advanced gastric or gastro-oesophageal …

Standard first-line chemotherapy results in disease progression and death within one year in
most patients with human epidermal growth factor receptor 2 (HER2)-negative gastro …

Gastric cancer and gastro-oesophageal junction cancer represent a global health-care
challenge. Despite the efficacy of improved chemotherapy and surgical options, these …

Background First-line chemotherapy for advanced or metastatic human epidermal growth
factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma …

Oesophageal cancer is the seventh most common cancer worldwide, with 604 000 new
cases diagnosed in 2020. It is the sixth most common cause of cancer-related mortality, with …

Immune-checkpoint inhibitors targeting PD-1 or PD-L1 have already substantially improved
the outcomes of patients with many types of cancer, although only 20–40% of patients derive …